GERON CORP (GERN) Stock
5 of the hedge funds AlphaScala tracks reported GERN in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $37.17M.
Which hedge funds own GERN?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 29.04M | $37.17M | +35% |
| Millennium Management Israel Englander | 8.11M | $10.38M | +11% |
| Renaissance Technologies Jim Simons (founder) | 4.58M | $5.86M | +154% |
| Point72 Steve Cohen | 4.05M | $5.18M | -80% |
| D.E. Shaw David Shaw | 124K | $158.6K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →GERN price chart
Powered by TradingViewWhat does GERON CORP do?
Geron Corporation is a commercial-stage biopharmaceutical company focused on blood cancers and myeloid hematologic malignancies through telomerase inhibition. The company's primary product is RYTELO (imetelstat), a first-in-class telomerase inhibitor approved in the United States and the European Union for adult patients with lower-risk myelodysplastic syndromes who have transfusion-dependent anemia. RYTELO demonstrated strong commercial momentum, with net product revenue growing substantially as the company expanded its U.S. commercial efforts and clinical development programs. Geron is also advancing the Phase 3 IMpactMF trial to explore potential label expansion in myelofibrosis, alongside investigator-sponsored and real-world evidence studies. The company pursues a focused strategy on hematology-oncology, leveraging telomerase inhibition as a mechanism to address blood cancers. Founded in 1990 and headquartered in Foster City, California, Geron operates as a single-segment organization dedicated to bringing innovative therapeutic options to patients with serious blood disorders and malignancies.